Eli Lilly was down 0.9%, following a 6.6% drop on Tuesday, after reporting fourth-quarter sales of blockbuster GLP-1 medicines Zepbound and Mounjaro ... Israeli and Arab officials have said ...

In this week’s Roundtable installment, No. 2 of three, we’ve collected 34 picks from five of the pros, plus their supporting commentary. The group includes Henry Ellenbogen, chief investment ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli ... Lilly’s CEO, David Ricks, credited the move to an overestimation of the pace of growth for Mounjaro and ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

On Thursday, Eli ... Lilly’s Ulcerative Colitis Drug For Crohn’s Disease The company reported an adjusted EPS of $5.32, compared to $2.49 from a year ago, beating the consensus of $4.94 ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...